<DOC>
	<DOCNO>NCT02157298</DOCNO>
	<brief_summary>Japanese male female patient Type 2 Diabetes age ≥ 20 year old , inadequate glycemic control insulin define Haemoglobin A1c ≥ 7.2 % &lt; 11 % enrol wash-out phase directly lead-in phase depend whether patient receive Oral antidiabetic drug ( include Glucagon-Like Peptide-1 agonist exclude Thiazolidinedions ) Dipeptidyl Peptidase-4 inhibitor part baseline treatment . Additional treatment concomitant Dipeptidyl Peptidase-4 inhibitor allow . And around 180 eligible patient total randomize study 2:1 randomization scheme ( i.e.120 patient dapagliflozin treatment group 60 patient placebo treatment group . All subject complete 16 week double-blind treatment period shift 36 week open extension treatment period .</brief_summary>
	<brief_title>Phase IV Study With 36-week Extension Period Evaluate Efficacy Safety Dapagliflozin Therapy When Added Therapy Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control Insulin .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Diagnosis Type 2 Diabetes accord criterion specify Japan Diabetes Society Japanese Men woman age ≥ 20 year time consent . Stable ( unless adjustment require base Fasting Plasma Glucose value ) dose insulin* monotherapy mean insulin [ two type insulin within authorize indication Japan ] dose ≥ 0.2 IU/kg/day AND ≥ 15 IU/body/day past 8 week prior enrolment . HbA1c ≥ 7.2 % &lt; 11 % blood sample collect Visit 1 ( enrolment ) Visit 3 , observed central laboratory Diagnosis Type 1 diabetes mellitus , know diagnosis Maturity Onset Diabetes Young , secondary diabetes mellitus diabetes insipidus History diabetic ketoacidosis . Thyroidstimulating hormone free T4 value outside normal range , observed central laboratory ; abnormal Thyroidstimulating hormone value need follow free T4 test . Patients abnormal free T4 value exclude Visit 1 Fasting Plasma Glucose &gt; 240 mg/dL ( twice row ) despite permit dose adjustment insulin therapy washout period leadin period . Recent cardiovascular event patient . eGFR &lt; 45 mL/min/1.73 m2 Visit 3 , observed central laboratory . History unstable rapidly progress renal disease . History unexplained microscopic gross hematuria , microscopic hematuria Visit 1 , confirm followup sample next scheduled visit , accord investigator satisfactory evaluation hematuria conduct . Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN , observed central laboratory Visit 1 . Total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) , observed central laboratory Visit 1 . Positive serologic evidence current infectious liver disease include Hepatitis A viral antibody IgM , Hepatitis B surface antigen Hepatitis C virus antibody , observed central laboratory . Haemoglobin &lt; 10 g/dL ( &lt; 100 g/L ) 6.2 mmol/L men ; haemoglobin &lt; 9.0 g/dL ( &lt; 90 g/L ) 5.9 mmol/L woman , observed central laboratory Visit 1 . History chronic haemolytic anaemia haemoglobinopathy ( example , sickle cell anaemia , thalassemia , sideroblastic anaemia ) . Mild haemolysis due artificial heart valve due sickle cell trait exclusion criterion except haemoglobin level low ( define haemoglobin criterion ) . History malignancy within last 5 year prior enrolment , exclude successful treatment basal squamous cell skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Japanese patient type 2 diabetes inadequate glycemic control insulin</keyword>
</DOC>